Pegvisomant News and Research

RSS

New federally-funded research project could lead to treatments that extend human lifespan

A new federally-funded research project at the Ohio University Edison Biotechnology Institute and Heritage College of Osteopathic Medicine could lead to treatments that extend human lifespan and allow people to enjoy better health in their old age.

21 Sep 2018

Endocrine Society announces winners of prestigious 2019 Laureate Awards

The Endocrine Society today announced it has chosen 13 leading endocrinologists as winners of its prestigious 2019 Laureate Awards, the top honors in the field.

6 Sep 2018

Kopchicks' $10.5 million gift to fund student fellowships at MD Anderson UTHealth Graduate School

Just as he has changed the lives of people suffering from a devastating genetic disease, molecular endocrinologist John J. Kopchick, Ph.D., and his wife, Charlene, of Athens, Ohio, are paving the way for future scientists to do the same with a transformative $10.5 million gift to The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences.

23 Jun 2017

Acromegaly and antisense therapy: an interview with Mark Diamond, CEO Antisense Therapeutics

Acromegaly is a chronic, life-threatening disease triggered by a benign tumour of the pituitary gland causing excessive growth hormone release. Oversupply of growth hormone stimulates liver, fat and kidney cells to produce excess levels of Insulin-Like Growth Factor I (IGFI), which causes abnormal growth of the bones of the hands, face and feet and bodily organs.

26 Aug 2014

New guidelines for the treatment of acromegaly, a serious growth hormone disorder

It’s said a lot can happen in seven days. In seven years, a lot has happened in the understanding of acromegaly, a debilitating condition that causes a patient to have too much growth hormone. It’s seven years since the American Association of Clinical Endocrinologists last produced guidelines for the diagnosis and treatment of acromegaly. Their 2004 guidelines were just 13 pages long. Their latest, the 2011 guidelines, have grown – to 44 pages.

31 Aug 2011

Pegvisomant News and Research

New federally-funded research project could lead to treatments that extend human lifespan

Endocrine Society announces winners of prestigious 2019 Laureate Awards

Kopchicks' $10.5 million gift to fund student fellowships at MD Anderson UTHealth Graduate School

Acromegaly and antisense therapy: an interview with Mark Diamond, CEO Antisense Therapeutics

New guidelines for the treatment of acromegaly, a serious growth hormone disorder

Breaking Barriers: ANDYSMANCLUB's Fight for Men's Mental Health on World Mental Health Day

Arrayed CRISPR Screening for Revolutionizing Target Discovery

Innovations in baculovirus–insect cell expression systems

Latest News